Paysign beats Q3 revenue estimates

Overview

• Paysign Q3 revenue grows 41.6% yr/yr, beating analyst expectations

• Adjusted EBITDA for Q3 beats consensus, reflecting improved operational efficiency

• Pharma patient affordability revenue grows 141.9%, driving overall revenue growth

Outlook

• Paysign expects full-year 2025 revenue between $80.5 mln and $81.5 mln

• Company anticipates flat plasma revenue in Q4 2025

• Paysign projects full-year 2025 Adjusted EBITDA between $19 mln and $20 mln

Result Drivers

• PHARMA REVENUE GROWTH - Pharma patient affordability revenue increased 141.9% yr/yr, driven by 39 net new programs and increased fees

• PLASMA REVENUE GROWTH - Plasma revenue increased 12.4% yr/yr, supported by 117 net new plasma centers despite lower average revenue per center

• SERVICE EXPANSION - New customer service contact center expanded support capacity fourfold, aiding in meeting surging demand

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the business support services peer group is "buy"

• Wall Street's median 12-month price target for Paysign Inc is $9.00, about 42.7% above its November 11 closing price of $5.16

• The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 47 three months ago

Press Release: ID:nBw2WHj83a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)